JY
KYTX icon

Jeff Yass’s Kyverna Therapeutics KYTX Stock Holding History

Jeff Yass’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$315K Buy
35,300
+12,800
+57% +$114K ﹤0.01% 10937
2026
Q1 		$194K Sell
22,500
-16,600
-42% -$138K ﹤0.01% 11739
2025
Q4 		$368K Sell
39,100
-7,800
-17% -$57.9K ﹤0.01% 9478
2025
Q3 		$281K Buy
46,900
+18,300
+64% +$73.2K ﹤0.01% 10275
2025
Q2 		$87.8K Buy
+28,600
New +$70.7K ﹤0.01% 11861
2025
Q1 		– Sell
-19,800
Closed -$74.1K – 13615
2024
Q4 		$74.1K Buy
+19,800
New +$94.9K ﹤0.01% 11512

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Jeff Yass's KYTX Position: Q2 2026 in Review

Jeff Yass reduced its Kyverna Therapeutics (KYTX) stake by 73% in Q2 2026, selling an estimated $3.74M and leaving 155,800 shares worth $1.39M. The position accounts for ﹤0.01% of the portfolio, ranked #7348.

Jeff Yass first reported a position in KYTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $4.98M in Q1 2026. 119 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Jeff Yass held 155,800 shares of Kyverna Therapeutics worth $1.39M as of Q2 2026.
  • Jeff Yass sold 421,800 Kyverna Therapeutics shares in Q2 2026, an estimated $3.74M.
  • Kyverna Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #7348 holding.
  • Jeff Yass first reported a position in Kyverna Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Jeff Yass's Kyverna Therapeutics position peaked at $4.98M in Q1 2026.
  • 119 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.